KPV Dosage Chart & Schedule Guide.

No. A PubMed sweep of the KPV literature returns animal models, cell culture and review articles: no completed randomised human trial and no registered ClinicalTrials.gov entry. The strongest work is Dalmasso 2008 (mouse DSS and TNBS colitis), Kannengiesser 2008 (mouse DSS and CD45RBhi transfer colitis) and Viennois 2016 (13 weeks of continuous dosing in APC-Min mice). Every human dose you will see quoted anywhere, including the 500 mcg on this page, is a convention that grew out of compounding practice rather than a number any trial produced. That does not make it wrong, but it does mean nobody has established a therapeutic dose, a toxic dose, or the gap between them.

No, and avoiding exactly that is the reason KPV exists as a separate molecule. KPV is the final three amino acids of α-MSH, positions 11–13. The 2008 Endocrine Reviews review by Brzoska and colleagues describes KPV specifically as the fragment that keeps α-MSH's anti-inflammatory action while losing its pigmentary action, which is what makes it a candidate for anti-inflammatory therapy where the parent hormone was unusable. Kannengiesser tested the receptor question directly: KPV still rescued mice engineered with a non-functional MC1 receptor from lethal colitis, meaning it works without the melanocortin receptor that drives tanning. KPV is not Melanotan and shares none of its pigment, nausea or libido effects.

If your target is the gut, there is a genuine argument for it. KPV is transported intact by PepT1, which is precisely why the animal work delivered it in drinking water, and PepT1 is upregulated in inflamed colon so the drug concentrates where the inflammation is. For skin, joint or systemic inflammation the oral case is weaker, because you are then relying on KPV reaching PepT1-expressing immune cells in circulation, and nobody has measured that in a human. A lot of people run oral for gut complaints and subcutaneous for everything else. Neither route has human pharmacokinetic data, so this is reasoning from mechanism, not from evidence.

KPV produces no acute sensation at all (no flush, no stimulation, no appetite change), so the first few days give you nothing to go on, and that is expected rather than a bad sign. In the colitis models the earliest measurable change was faster weight recovery across an 8-day course. Give it three to four weeks before forming a judgement, and track something concrete you can compare against baseline: stool frequency and urgency, a photo of the skin, a pain score. If nothing has moved by week four, raising the dose is not a documented path to a response.

Nobody has published one for humans. KPV is a 342 Da tripeptide (C16H30N4O4), and unmodified tripeptides are cleaved by serum aminopeptidases within minutes. A 2018 PLoS One paper had to glyco-alkylate the lysine residue specifically to give KPV analogues stability against proteolytic enzymes, which tells you the native molecule does not have much. The 'two to three hour half-life' repeated across peptide retail sites has no traceable source. Practically: dose daily, dose consistently, and do not expect meaningful 24-hour blood levels from a single injection.

KPV and BPC-157 are frequently stacked and no interaction is known, but no study has examined the combination either, so you are the experiment. The more important answer is the second half: do not substitute KPV for prescribed IBD therapy. No trial has compared it to mesalamine, a steroid or a biologic, and the mouse studies were rescue experiments in induced colitis, not head-to-head comparisons against standard care. If you are already on a biologic or another immunosuppressant, speak to the prescriber first; KPV suppresses the same NF-κB and TNF-α axis those drugs target, and layering immune suppression has never been tested.

This claim is repeated everywhere and it is shakier than it sounds. Early reviews of α-MSH-derived peptides reported antimicrobial activity against gram-positive organisms and Candida, and that is where the claim originates. But the 2018 PLoS One study that set out to test it directly found no antimicrobial activity for Ac-KPV-NH2 under a range of assay conditions, nor for its modified analogues. Treat 'KPV is antimicrobial' as unsettled rather than established, and do not choose KPV over an actual antimicrobial on that basis.

Add 2 mL of bacteriostatic water slowly, running it down the inside wall of the vial. Never squirt it directly onto the powder, and never shake. Swirl gently until the solution is clear. That gives 5,000 mcg/mL, so on a U-100 insulin syringe one unit equals 50 mcg: 250 mcg is 5 units, 500 mcg is 10 units, and 1,000 mcg is 20 units. Keep the reconstituted vial refrigerated and plan to finish it within roughly 28 days, since it is the benzyl alcohol in bacteriostatic water that preserves it; plain sterile water gives you no preservative and a much shorter window. Rotate injection sites around the abdomen to avoid building up lumps in one spot.